EMA reports that more than 90% of EU/EEA pharmacovigilance inspections run through national programmes. Therefore, inspection readiness must become part of daily PV operations, not a last-minute exercise. In 2026, good pharmacovigilance practice (GVP) gives teams the framework for that control. Pharmacovigilance professionals must connect the PSMF, QPPV oversight, signal management, risk plans, and audits. However, compliance depends on evidence showing these controls work consistently before inspectors arrive. This guide explains the key GVP modules, expected evidence, and practical inspection controls.
Table of Contents
What Is Good Pharmacovigilance Practice (GVP)?
Good pharmacovigilance practice (GVP) is the regulatory framework that guides how organisations manage medicine safety throughout a product’s lifecycle. It defines how teams organise, perform, document, monitor, and improve pharmacovigilance activities. Therefore, GVP helps companies maintain consistent processes for safety reporting, signal management, risk management, audits, and regulatory oversight. In addition, it supports clear responsibilities, reliable records, and effective quality controls. Strong GVP implementation helps teams protect patients while maintaining inspection-ready pharmacovigilance systems.
Why Does GVP Matter During Pharmacovigilance Inspections?
GVP matters during pharmacovigilance inspections because regulators test whether documented controls work in daily practice. Inspectors review how teams manage safety data, signals, risks, responsibilities, and quality records. Therefore, written procedures alone are not enough. Companies must show consistent execution, clear oversight, and reliable evidence. In addition, inspectors look for gaps between procedures and actual operations. Strong GVP controls help organisations demonstrate compliance, protect patients, and maintain inspection readiness.
How the GVP Framework Controls Pharmacovigilance Compliance
The GVP framework links responsibilities, processes, and quality controls across key pharmacovigilance activities. Clear documentation and consistent implementation help teams demonstrate compliance, protect patients, and maintain inspection-ready evidence.
The following four areas show how GVP turns pharmacovigilance requirements into practical, inspection-ready controls.
- Pharmacovigilance System Master File and QPPV Oversight (PDF Available)
- Risk-Based Pharmacovigilance Audits (PDF Available)
- Risk Management Plans and Lifecycle Safety Controls (PDF Available)
- Signal Management and Regulatory Safety Decisions (PDF Available)
This infographic shows how a pharmacovigilance system moves from defined GVP controls to documented evidence that inspectors can verify.
Pharmacovigilance System Master File and QPPV Oversight (PDF Available)
The PSMF describes how an organisation structures and operates its pharmacovigilance system. It also supports QPPV oversight by documenting responsibilities, processes, quality controls, performance, and system changes.
Risk-Based Pharmacovigilance Audits (PDF Available)
Risk-based pharmacovigilance audits assess whether PV systems meet GVP requirements. They focus audit resources on areas with the highest patient-safety and compliance risks.
Risk Management Plans and Lifecycle Safety Controls (PDF Available)
Risk Management Plans describe identified and potential risks, missing safety information, and measures used to manage those risks. They should evolve throughout the medicine lifecycle as new safety evidence changes the product’s benefit-risk profile.
Signal Management and Regulatory Safety Decisions (PDF Available)
Signal management evaluates new safety information to identify potential risks. Its findings can guide regulatory actions, including label changes, monitoring, or additional risk controls.
Which GVP Modules Matter Most During an Inspection?
GVP inspections do not focus on one module in isolation. Inspectors connect pharmacovigilance requirements with the people, processes, systems, and records that demonstrate effective control. Therefore, teams must show that written procedures match daily operations. They should also demonstrate clear QPPV oversight, timely safety activities, traceable decisions, and effective quality controls. However, the exact inspection scope depends on the products, risks, previous findings, and pharmacovigilance activities involved.
The table below shows how major GVP modules translate regulatory requirements into accountable activities, controlled records, and practical inspection evidence.
| GVP Module | Main Requirement | Key Accountable Roles | Typical Controlled Evidence | Common Inspection Focus |
|---|---|---|---|---|
|
Module I – PV Systems and Quality Systems |
Establish and maintain an effective pharmacovigilance system supported by a functioning quality system. |
QPPV, PV management, quality personnel |
SOPs, training records, quality objectives, compliance metrics, business continuity records, CAPA |
Governance, resources, training, procedural compliance, system performance, deviations and CAPA effectiveness |
|
Module II – PSMF |
Maintain an accurate and current Pharmacovigilance System Master File describing the PV system. |
QPPV, PSMF owner, PV quality |
PSMF, annexes, organisational charts, system descriptions, delegation records, change history |
PSMF accuracy, QPPV oversight, outsourced activities, safety-data sources, system changes and document currency |
|
Module IV – Pharmacovigilance Audits |
Operate a risk-based audit programme and address significant audit findings. |
PV auditors, quality manage |
Audit strategy, audit plans, reports, findings, CAPA plans, follow-up evidence |
Audit independence, risk-based planning, critical or major findings, CAPA completion and effectiveness |
This infographic maps key GVP modules to their main requirements, supporting evidence, and areas that inspectors may examine during pharmacovigilance inspections.
How Should PV Teams Prepare for a GVP Inspection?
PV teams should prepare for a GVP inspection by checking whether processes, records, system access, owners, and corrective actions are current and easy to trace. First, confirm that procedures match daily practice and that responsibilities remain clear. Then, review key evidence such as the PSMF, audit findings, CAPAs, signal records, case-processing data, and training files. In addition, teams should test how quickly they can retrieve requested documents. Strong preparation helps reduce delays, expose gaps early, and demonstrate consistent pharmacovigilance control.
Final Words
EMA recorded 10 centrally requested pharmacovigilance inspections in 2025, reflecting an increasingly risk-based approach to regulatory oversight. Therefore, fewer inspections should not be confused with lower expectations. Regulators are focusing resources on higher-risk and higher-impact areas. For PV teams, good pharmacovigilance practice (GVP) must remain part of daily operations, not just inspection preparation. Ultimately, current records, traceable decisions, effective CAPAs, and clear system ownership provide the strongest evidence of sustained compliance.
Quality Management System
We work with pharmaceutical teams to design, implement, and run effective Quality Management Systems, covering change control, CAPA, deviations, and audits to support consistent GMP compliance.
FAQ
PV teams should have the current PSMF, SOPs, training records, safety-review records, audit evidence, vendor agreements, signal documentation, and CAPA records readily available. Inspectors may request additional evidence before or during the inspection.
Inspectors check whether documented GVP controls work in practice. They may review safety databases, case processing, signal management, QPPV oversight, risk management, audits, quality systems, outsourced activities, and regulatory reporting.
Teams should investigate each finding, identify the root cause, define risk-based corrective and preventive actions, assign owners and deadlines, and document completion. They should also verify CAPA effectiveness to show that the underlying compliance problem has been controlled.
References
Marco Klinger is Head of Quality Services at Zamann Pharma Support, where he leads consulting teams through complex regulatory and quality-driven projects. He brings more than 15 years of hands-on compliance experience across regulated industries. His work includes close collaboration with companies such as Reckitt, Sanofi, Biotech, Biotest, and others. Marco has deep expertise in medical device development, aseptic manufacturing, and the design, implementation, and management of complete quality management systems within GMP-regulated environments.